Introduction
One of the most prominent neuropathological hallmarks in the brains of Alzheimer's disease (AD) patients is the deposition of senile plaques. These plaques are extracellular lesions that are primarily composed of b-amyloid (Ab). Ab is a 40-or 42-aminoacid peptide that is derived from the amyloid precursor protein (APP) by proteolytic processing. Genetic and neuropathological studies provide strong evidence for a central role of Ab in the pathogenesis of AD. [1] [2] [3] [4] Ab is a highly fibrillogenic peptide that is prone to aggregate into 6 to 10 nm diameter fibrils with the characteristic cross-b structure. [5] [6] [7] Initial studies have shown that the aggregation of Ab into fibrils is a prerequisite for its toxicity. [8] [9] [10] Later studies demonstrated the neurotoxicity of different prefibrillar intermediates in the Ab aggregation pathway. [11] [12] [13] [14] [15] [16] [17] These different aggregation states might mediate different toxic effects at different stages of the disease. [18] Protofibrils (PF) [19] for example, are intermediates on the pathway towards mature fibrils. PF are short (10-200 nm) soluble curvilinear structures that have several characteristics of mature fibrils (high b-sheet content, and a fibril-like structure). Like fibrils, PFs have also been shown to induce neurotoxicity in culture, and acute electrophysiological changes. [11] The exact nature of the Ab species that causes toxicity and eventually neurodegeneration in vivo is not known, but these studies do indicate that Ab must be in an aggregated state to be toxic. This suggests that the prevention of Ab aggregation might inhibit Ab neurotoxicity.
Previous studies on the aggregation process of Ab identified the critical region that is involved in amyloid fibril formation. [20, 21] The hydrophobic core at residues 16-20 of Ab, KLVFF, are crucial for the formation of b-sheet structures by Ab. It was also shown that KLVFF binds to the homologous sequence in Ab and prevents its aggregation into amyloid fibrils. [22, 23] This KLVFF sequence has served as a lead compound for the development of inhibitory agents that are aimed at preventing Ab aggregation in vivo. [24, 25] KLVFF has also been shown to reduce amyloid deposits in vivo. [26] The use of multiple simultaneous interactions to enhance the affinity and specificity of binding, known as multivalency, is an important concept in biology. In the past, different types of scaffold molecules have been used to obtain multivalent structures, such as colloidal gold particles [13] and poly(ethylene glycol) (PEG). [25] A disadvantage of these approaches is the large size of the particles (PEG) and the lack of control over
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the number of peptides attached (colloidal gold). These dis-A C H T U N G T R E N N U N G advantages are circumvented when using denA C H T U N G T R E N N U N G driA C H T U N G T R E N N U N G mers. Dendrimers are multivalent macromolecules with regular, highly branched structures and dimensions that resemble those of small proteins; they have been used in several different biological applications. [27] In this study we have synthesized a firstgeneration KLVFF dendrimer by using native chemical ligation, [28] thereby generating a small, well-defined molecule that is capable of making multivalent interactions. We have investigated the effect of dendritic KLVFF on the aggregation of low molecular weight (LMW) Ab 1-42 as well as its effects on preformed aggregates.
Our data show that the coupling of KLVFF to a dendrimeric scaffold potentiates its inhibitory effect on Ab 1-42 aggregation as well as on the disassembly of pre-existing aggregates. Thus, our studies indicate that a dendrimer that contains multiple copies of KLVFF might have therapeutic potential in Alzheimer's disease.
Results

Synthesis and characterization of fibrillogenesis inhibitor compounds
The peptide-dendrimer complexes in this study were synthesized by using native chemical ligation. Four equivalents of the MPAL thioester of KLVFFGG (K 1 ) were ligated to one equivalent of the cysteine dendrimer C 4 (see the dotted box in Scheme 1); this resulted in the formation of the [KLVFFFGG] 4 dendrimer (K 4 ). The chemical structures of K 1 and K 4 are shown in Scheme 1. The identity and purity of the peptides were verified by MALDI-TOF (see Figure S1 )
Aggregation properties of the KLVFF compounds
Before assessing the performance of K 1 and K 4 as inhbitors of Ab 1-42 aggregation, we first studied the possible self-aggregation of these KLVFF peptides. Neither K 1 nor K 4 showed Thioflavin T (ThT) binding after incubation for 24 h at 37 8C. (Figure 1 A) . Increasing the aggregation time of either compound up to 5 days did not lead to an increase in ThT fluorescence (not shown). Morphological analysis by AFM showed the absence of fibrillar aggregates in the K 4 sample; this confirms the results from the ThT assay (Figure 1 B) . Only globular structures, with a diameter of 20-80 nm and height of 10-15 nm were A C H T U N G T R E N N U N G observed after aggregation at 37 8C for 24 h (Figure 1 B) . These data indicate that the dendritic KLVFF compound does not form fibrils or other structures with high b-sheet content.
Dendritic KLVFF is a more potent inhibitor of LMW Ab A C H T U N G T R E N N U N G aggregation than monomeric KLVFF LMW Ab was prepared as described in the Experimental Section. Electron microscopy (EM) analysis showed, as expected for LMW Ab, only very few oligomer-like structures at t = 0 (Figure 2 To show that the effect of K 4 on Ab 1-42 aggregation is specifically caused by the KLVFF sequence, a similar co-aggregation experiment was performed on LMW Ab 1-42 with a dendrimer that contained four peptides, each with five non-Ab-related amino acids (GRGDS) with a GG spacer (G 4 ). G 4 had no inhibitory effect on Ab 1-42 aggregation even at the highest ratio used (1:4). This result shows that the effect caused by K 4 is mediated by the Ab-derived sequence KLVFF.
Dendritic KLVFF disassembles mature Ab 1-42 fibrils
To test whether the KLVFF derivatives can also cause the disassembly of mature Ab 1-42 fibrils (fAb), fAb was incubated with K 1 and K 4 for 24 hours in different ratios. 
Purification and characterization of protofibrillar Ab 1-42
To study the effect of the inhibitory agents on preformed protofibrils (PF), we prepared highly enriched PF Ab aggregates as described in the Experimental Section. The PF fraction was separated from the LMW forms of 
Dendritic KLVFF interferes in protofibril-to-fibril conversion by disassembling protofibrils
To study the effect of the K 4 peptide dendrimer on PF aggregates, SEC-purified PF Ab 1-42 was aggregated for 24 h in presence or absence of K 1 and K 4 in different ratios. ThT analysis showed that K 4 interferes in the protofibril-to-fibril conversion 
Discussion
One of the key pathogenic factors in AD is the Ab peptide. Ab aggregates into fibrils via several intermediate aggregation species. Different aggregated species might exert different toxic effects, [18] for example, our own previous work showed the induction of endoplasmic reticulum stress with oligomeric, but not with fibrillar Ab aggregates. [29] Nevertheless, plaques in AD patients consist mainly of fibrillar Ab aggregates. Fibrillar Ab has been shown to be toxic in culture, and might also be responsible for the neuronal loss that is observed in AD patients. In any case, it is clear that aggregation of Ab is a prerequisite for toxicity, therefore the prevention of Ab aggregation might inhibit Ab-induced neurotoxicity. To this end, we investigated intervention in Ab 1-42 aggregation by using a multivalent KLVFF variant. We successfully produced a dendritic variant of KLVFF by using native chemical ligation. Like the monomeric K 1, the dendritic K 4 shows no self-aggregation, not even after prolonged incubation at 37 8C, which is important for downstream applications that require a soluble agent.
In this study the effect of the branched KLVFF structure (K 4 ) was compared to the monomeric KLVFF (K 1 ). Because different Ab species are known to contribute to AD pathogenesis, intervention of Ab aggregation was studied at different aggregation stages of Ab: the first onset of aggregation (LMW), the aggregation of intermediate species (PF) and the aggregated mature fibrils (fAb). To prevent Ab from reaching an aggregated state, we intervened at the first onset of aggregation by starting from the LMW state. K 4 was found to be highly effective in preventing LMW Ab 1-42 aggregation, and to be much more potent than K 1 , as indicated by both the amount of fluorescence reduction at the same 1:4 ratio for K 1 (30 %) and K 4 (90 %) as well as the 20-fold lower concentration of K 4 (per peptide subunit) that was needed for a similar inhibition as K 1 . Previously, a branched hexameric retro-inverso FFVLK was shown to increase the potency of Ab 1-40 aggregation inhibition. [25] The multivalent effect that is reported in this study was threefold of a hexamer compared to a dimeric conjugate; this indicates that the K 4 conjugate from our study gives a stronger multivalent effect. However, a direct comparison of the data is difficult because another study showed that a KLVFF analogue is a more potent inhibitor of Ab 1-40 than of Ab 1-42 aggregation, [30] and because vastly different Ab and conjugate concentrations were used. Another possibility for aggregation intervention is the disassembly of preformed fAb. Previous studies have shown that KLVFF analogues are capable of disassembling preformed fibrils. [30, 31] Our study also shows that K 4 disassembles fAb in a concentration-dependent manner and in a more potent way than K 1 ; this was indicated by both the amount of ThT fluorescence reduction at the same 1:16 Ab/K ratio for K 1 (25 %) and K 4 (65 %), as well as the 40-fold lower concentration of K 4 (per peptide subunit) that was needed to induce similar inhibition to K 1 . It should be noted however, that even the highest concentration of K 4 did not cause a complete breakdown of the fibrils; about 35 % of potentially toxic amyloid fibrils remained in solution. This might be a drawback for the potential use of K 4 as a therapeutic agent in fibril breakdown. In contrast, the previously reported hexameric PEG-FFVLK conjugate was not capable of inducing fibril disassembly. [25] This might be due to the use of the PEG scaffold, which is relatively large (10 kDa) compared to the first generation dendrimer (729 Da).
Because PF are intermediate species on the pathway to fibrillization, they are an excellent experimental model to study both aggregation inhibition and the breakdown of pre-exisiting aggregates in one experimental setup. In addition, PF have been shown to have diverse toxic effects in vitro. [11] An early onset variant of AD, caused by the "Arctic" mutation in APP is shown to result in accelerated production of PF; [32] this indicates the relevance of PF for AD pathogenesis. We show that K 4 also has a more potent inhibitory effect than K 1 for the aggregation from PF to fAb . This is best indicated by the fact that an Ab/K ratio (for K 1 ) of 1:8 results in inhibition of the PF-tofAb conversion by 55 % whereas the same ratio for K 4 results in PF breakdown of 55 %. ThT analysis shows a concentration-dependent effect of K 4 on PF aggregation; lower concentrations inhibit the further aggregation of fibrils, and higher K 4 concentrations cause increased PF disassembly. We also show that K 4 rearranges PF Ab 1-42 into amorphous aggregates. This is different from the disassembly of preformed fibrils into globular more oligomer-like structures, and it suggests that there is a different mechanism for the disassembly of protofibrils by K 4 .
Our study shows that K 4 is much more potent than K 1 and thus has a multivalent inhibitory effect on all of the aggregation species that were studied. The effect of K 4 on the inhibition of LMW aggregation compared to the breakdown of pre-formed fibrillar aggregates, however, occurs with different kinetics as indicated by the concentrations of K 4 that are needed for half-maximal inhibition. The half-maximal inhibition for aggregation of 10 mm Ab is attained with 1.25 mm K 4 . To reach half-maximal disassembly of 10 mm fibrils, however, a more than fivefold higher K 4 concentration of 6.75 mm is required. This suggests that K 4 exerts its effect predominantly on LMW Ab. Because fAb is in equilibrium with LMW species, this suggests that the strong effect of K 4 on LMW Ab will shift this equilibrium between fAb and LMW towards the LMW state, and thus cause a disassembly of existing fibrillar aggregates.
Previous studies have shown an inhibitory effect of nonfunctionalized amine-terminated polyamine dendrimers on amyloid formation by Ab 1-28 and prion protein (PrP) fragments. [33] [34] [35] [36] Ab aggregation was inhibited by third-generation amine-terminated polyamine dendrimers, and the inhibition increased with A C H T U N G T R E N N U N G increasing dendrimer concentration and generation. To show that the multivalent effect of K 4 was specifically caused by the KLVFF sequence and not by the dendritic structure itself, we performed similar aggregation assays with a dendrimer that consisted of 4 unrelated pentapeptides (G 4 ). Co-incubation of G 4 and Ab caused only a small inhibition of LMW Ab 1-42 ag- www.chembiochem.org gregation, and had no effect on fibril breakdown in any of the Ab/G 4 ratios that were studied. The cysteine-dendrimer (C 4 ) showed only a minor effect on fibril breakdown; this also suggests that it is unlikely that the amine-terminated PPI dendri-A C H T U N G T R E N N U N G mers would have an effect on Ab aggregation. This result clearly shows that the more potent effect of K 4 on Ab 1-42 aggregation is sequence specific. The potency of a multivalent KLVFF derivative might be enhanced by using a higher generation dendrimer, but this is likely to also enhance sequence-unspecific effects, as observed with the third and higher generation amine-terminated polyamine dendrimers. [34, 35] In addition, with increasing generation, the hydrophobicity will increase, as well as its size and shape, thereby loosing the advantage of a soluble small-size inhibitor.
Although we can not fully exclude the possibility that the strong inhibiton caused by K 4 is caused by steric hindrance by the attachment of any structure to KLVFF, the strongly increased potency of K 4 relative to K 1 suggests a multivalent effect. This multivalent effect might also apply for other potent KLVFF-derived aggregation inhibitors. Delivery across the blood-brain barrier (BBB) might be important for a therapeutic agent for AD. However, a study in mice showed that a monoclonal antibody against Ab can still be effective when applied in the periphery. [37] Injection of this antibody was shown to produce a "sink" effect by drawing soluble Ab from the brain into the bloodstream. This could then potentially halt or even reverse plaque formation. Whether dendritic KLVFF can work in a similar manner awaits further study. In addition, modifications can facilitate passage across the BBB. An analogue of the KLVFF peptide that was protected against proteolytic degradation, and that had increased BBB permeability has been successfully used in a rat model of brain amyloidosis. [26] It was shown to prevent Ab-induced spatial memory impairments, and caused a partial reduction of amyloid deposits. Our data suggest that dendritic derivatives of KLVFF might further increase its efficacy. In addition, several small-molecule inhibitors have also been shown to inhibit amyloid aggregation, [38] and their efficacy might also be further increased via multivalent display on dendrimers. Dendrimers might thus be a valuable tool that can increase the therapeutic efficacy of many aggregation inhibitors.
The small size and controlled synthesis of dendrimeric structures is a major advantage when creating multivalent molecules. In this study, we have employed this advantage to create a small, multivalent and sequence-specific inhibitor of Ab aggregation. The effect of K 4 on the inhibition of fibril formation as well as fibril disassembly suggests that many of the steps of Ab fibrillogenesis are reversible. Because K 4 acts on all different aggregation species, it has potential for use as a therapeutic agent.
Experimental Section
Synthesis of peptide-dendrimer conjugate: In this study native chemical ligation was used for the generation of peptide dendri-A C H T U N G T R E N N U N G mers. [28] Standard tert-butyloxycarbonyl (t-Boc)-mediated solidphase peptide synthesis was used to make the KLVFFGG peptide. The two glycine residues (GG) were included to provide a spacer between the KLVFF sequence and the dendrimer structure. The KLVFFGG peptides were functionalized with a C-terminal mercaptopropionic acid leucine (MPAL) thioester, as described in Hackeng et al. [39] Functionalization of the amine-terminated poly(propylene imine) dendrimers (kindly provided by DSM (Geleen, The Netherlands)) with cysteine residues, was done as described in van Baal et al. [28] Four equivalents of peptide thioester were ligated to one equivalent of the cysteine dendrimer by using standard ligation conditions (Tris buffer pH 7.5, 6 m guanidine, 2 % (v/v) thiophenol, 2 % A C H T U N G T R E N N U N G (v/v) benzylmercaptan, 37 8C), with stirring for 1 h at 37 8C. This resulted in the formation of [KLVFFGG] 4 dendrimer. The ligation product was further purified by using reversed-phase HPLC as described in van Baal et al. [28] The cysteine dendrimer is referred to as C 4 , KLVFFGG is referred to as K 1 and the [KLVFFGG] 4 dendrimer is reA C H T U N G T R E N N U N G ferred to as K 4 . As an additional control in the aggregation experiments, we used a dendrimer with 4 copies of the unrelated pentapeptide GRGDS with GG as a spacer (G 4 ). [28] All peptides and peptide dendrimers were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis, by using a-cyano-4-hydrocinnamic acid as a matrix. The MS data of the K 1 and K 4 structures are shown in the supplementary data. The MS data of G 4 as well as C 4 have been shown previously in van Baal et al. [28] Preparation and purification of different Amyloid-b 1-42 species: Purified Ab 1-42 peptide was purchased from California peptide (Napa, CA, USA) or Anaspec (San Jose, CA, USA). For the preparation of protofibrils, Ab 1-42 was initially diluted in DMSO, then in water, and finally in Tris-HCl, pH 7.4, to give final concentrations of 5 %, 25 mm and 1 mg mL À1 (222 mm) for DMSO, Tris and Ab, respectively. Large, insoluble particles (fibrils) were removed by a 5 min centrifugation step at 13 000 g at 4 8C. The supernatants were loaded onto a Superdex 75 HR 10/30 gel-filtration column (GE Healthcare Europe, Munich, Germany), and subsequently equilibrated with Tris-HCl (5 mm, pH 7.4), NaCl (75 mm) to separate PF from LMW species. The column was calibrated by using the following proteins as molecular mass standards: ribonuclease A (13.7 kDa), chymotrypsinogen A (25 kDa), ovalbumin (43 kDa) and albumin (67 kDa). The protein was eluted at a flow rate of 0.5 mL min À1 and 0.5 mL fractions were collected. To assess which eluted fractions from the PF or LMW peaks had the highest Ab 1-42 concentration, a sample of each of the fractions was run on a 16.5 % SDS gel and proteins were visualized by silver staining. For each peak the most intense bands on the gels (which contained the most of the Ab 1-42 peptide) were pooled and the concentration of the final mixture was determined by using a BCA protein assay (Pierce, Rockford, IL, USA), before the co-aggregation experiments were initiated. EM analysis was performed to confirm the protofibrillar structures.
To obtain LMW species, hexafluoroisopropanol (HFIP) was used as an initial solvent. Ab was dissolved in HFIP at a final concentration of 1 mg mL
À1
, aliquoted, and allowed to evaporate by using a SpeedVac centrifuge. The resulting peptide film was stored at À80 8C until further use. For co-aggregation experiments the peptide film was dissolved in DMSO, and sonicated in a bath sonicator for 10 min. For LMW preparation, Ab 1-42 was subsequently diluted in 5 mm Tris-HCl, pH 7.4, 75 mm NaCl buffer to a final concentration of 20 mm. EM analysis was performed to confirm the absence of fibrillar structures or other aggregates. This method has previously been shown to yield mainly monomeric and small soluble Ab species. [16] HFIP-treated LMW Ab species were also analyzed by SEC (not shown); they eluted from the column at approximately the same time as the SEC-purified LMW Ab separated from protofibrils. SEC-purified LMW Ab (not shown) as well as HFIP-treated Ab (Figure 2 B) showed very few structures on EM. These findings confirmed that LMW species that were obtained by either method were too small to be detected by EM as was previously reported. [11, 16, 19] Both LMW species also showed very low ThT binding. This indicated that they were similar structures. In addition, the same co-aggregation assays as with HFIP-treated LMW Ab (at 20 mm, see below), were also performed with the SEC-purified LMW Ab species at 10 mm (not shown) and showed similar results.
To obtain fibrillar Ab 1-42 (fAb) 10 mm HCl was added to Ab/DMSO under continuous vortexing to bring the peptide to a final concentration of 100 mm followed by incubating at 37 8C for 24 h. The fibrillar Ab 1-42 preparation was centrifuged (220 000 g) in a Beckman tabletop ultracentrifuge for 30 min at room temperature and the pellet was resuspended in 4 % DMSO/10 mm HCl (pH 4). The relative concentration of the fibrillar Ab 1-42 preparations was determined by a Bradford protein assay (Biorad, Hercules, CA, USA).
Co-aggregation assay: For the fibril disaggregation experiments, the fibrillar samples were further diluted in 5 mm Tris-HCl, pH 7.4, 75 mm NaCl buffer to a final concentration of 10 mm prior to the addition of K 1 or K 4 . For the protofibril aggregation experiments, isolated protofibril preparations were used at a final concentration of 10 mm in 5 mm Tris-HCl, pH 7.4, 75 mm NaCl in the presence or absence of the inhibitor peptides. Freshly prepared HFIP-treated LMW Ab was used at a final concentration of 20 mm in the co-aggregation assays. The samples were first incubated at 4 8C for 1 h to allow binding of the aggregation inhibitors to Ab . Subsequently, the samples were allowed to aggregate for 24 h at 37 8C. After 24 h samples were taken to perform a Thioflavin T assay and EM analysis.
Thioflavin T assay:
A 100 mm aqueous solution of Thioflavin T (ThT) was prepared and filtered through a 0.2 mm filter. The Ab aggregates were diluted to a final concentration of 5 mm into gly- The change in ThT fluorescence of LMW or PF Ab 1-42 after 24 h of aggregation in the absence of the interfering peptides was set at 100 %. The other experimental conditions were all related to this control. For the aggregation assays with fAb, the ThT fluorescence of fibrils in the absence of interfering peptides was set at 100 %.
Electron microscopy: Ab 1-42 preparations were adsorbed onto 300-mesh formvar/copper grids for 5 min and the excess fluid was filtered off. Subsequently, the samples were stained with 1 % uranyl acetate for 5 min, the excess fluid was removed and the grids were analyzed with a Philips EM-420 or a Philips CM 100 transmission electron microscope operated at 100 kV.
Atomic force microscopy (AFM): A total of 10 mL of each sample was adsorbed onto a freshly cleaved mica surface and was left to dry at room temperature for 1 h. AFM images were obtained at room temperature with a Nanoscope III (Digital Instruments, Santa Barbara, CA) by using force-volume mode operating in liquid.
Measurements were performed with a constant retraction speed of 355 nm s
À1
. Calibrated standard triangular Si 3 N 4 AFM cantilevers from Veeco (Santa Barbara, CA) were used with a 0.06 N m À1 nominal spring constant.
